trending Market Intelligence /marketintelligence/en/news-insights/trending/rrDLN6tlLG8h8BGANjdaAA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Aerie Pharmaceuticals completes $10M Avizorex Pharma acquisition

Aerie Pharmaceuticals Inc. has completed its acquisition of Avizorex Pharma SL in an all-cash deal worth $10 million.

The Durham, N.C.-based company previously said the acquisition will expand its eye disease product portfolio.

Avizorex's therapy AVX-012 has shown positive results during a phase 2a clinical trial in patients with dry eye disease. The drug acts on the TRPM8 protein, which is believed to play a role in treating dry eye disease, a common condition that occurs when tears are not able to provide adequate lubrication for the eyes.

Aerie also acquired the rights to other compounds that target TRPM8 through the Avizorex deal.